0001209191-21-025846.txt : 20210407
0001209191-21-025846.hdr.sgml : 20210407
20210407160840
ACCESSION NUMBER: 0001209191-21-025846
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210329
FILED AS OF DATE: 20210407
DATE AS OF CHANGE: 20210407
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Thornton Michael Milos
CENTRAL INDEX KEY: 0001706297
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37969
FILM NUMBER: 21812211
MAIL ADDRESS:
STREET 1: 3600 GREEN COURT, SUITE 350
CITY: ANN ARBOR
STATE: MI
ZIP: 48105
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ENDRA Life Sciences Inc.
CENTRAL INDEX KEY: 0001681682
STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
IRS NUMBER: 260579295
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3600 GREEN COURT
STREET 2: SUITE 350
CITY: ANN ARBOR
STATE: MI
ZIP: 48105
BUSINESS PHONE: 734-335-0468
MAIL ADDRESS:
STREET 1: 3600 GREEN COURT
STREET 2: SUITE 350
CITY: ANN ARBOR
STATE: MI
ZIP: 48105
FORMER COMPANY:
FORMER CONFORMED NAME: Endra Inc.
DATE OF NAME CHANGE: 20160805
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-03-29
0
0001681682
ENDRA Life Sciences Inc.
NDRA
0001706297
Thornton Michael Milos
3600 GREEN COURT, SUITE 350
ANN ARBOR
MI
48105
0
1
0
0
Chief Technology Officer
Common Stock
2021-03-29
4
S
0
18750
2.37
D
274960
D
Common Stock
2021-04-07
4
S
0
15000
2.53
D
259960
D
Stock Options
2.64
2021-04-05
4
A
0
50000
0.00
A
2031-04-05
Common Stock
50000
50000
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.35 to $2.39, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc., any security holder of ENDRA Life Sciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.50 to $2.56, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc., any security holder of ENDRA Life Sciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
This stock option grant becomes exercisable in three equal annual installments beginning April 5, 2022.
/s/ Michael M. Thornton by Mark Busch, attorney-in-fact
2021-04-07